To confirm the causal relationship between MAIT cells and immunotherapy responsiveness in NSCLC, we activated CD8+ MAIT cells with 5‐OP‐RU using a mouse subcutaneous tumor model and found that the tumor‐killing effect of the anti‐PD1 antibody was significantly improved. The gene discussed is CD8A; the disease is neoplasm.